Portage Biotech (ATON) Competitors

$0.33 +0.01 (+3.75%)

Closing price 04/20/2026

Extended Trading

$0.33 0.00 (0.00%)

As of 04/20/2026 07:59 PM Eastern

ATON vs. SNTI, BCTX, SKYE, LSTA, and TVGN

Should you buy Portage Biotech stock or one of its competitors? MarketBeat compares Portage Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Portage Biotech include Senti Biosciences (SNTI), Briacell Therap (BCTX), Skye Bioscience (SKYE), Lisata Therapeutics (LSTA), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.

How does Portage Biotech compare to Senti Biosciences?

Portage Biotech (NASDAQ:ATON) and Senti Biosciences (NASDAQ:SNTI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Senti Biosciences had 8 more articles in the media than Portage Biotech. MarketBeat recorded 9 mentions for Senti Biosciences and 1 mentions for Portage Biotech. Senti Biosciences' average media sentiment score of 1.08 beat Portage Biotech's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Portage Biotech has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A
Senti Biosciences	$20K	1,588.14	-$61.44M	-$3.19	N/A

Portage Biotech currently has a consensus target price of $2.00, indicating a potential upside of 502.41%. Senti Biosciences has a consensus target price of $8.75, indicating a potential upside of 757.84%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Portage Biotech has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Portage Biotech's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Senti Biosciences	N/A	-301.48%	-90.03%

13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Senti Biosciences beats Portage Biotech on 11 of the 15 factors compared between the two stocks.

How does Portage Biotech compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Portage Biotech (NASDAQ:ATON) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Portage Biotech is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Portage Biotech's return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Portage Biotech	N/A	N/A	N/A

Briacell Therap is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A

Briacell Therap has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, Briacell Therap had 6 more articles in the media than Portage Biotech. MarketBeat recorded 7 mentions for Briacell Therap and 1 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.00 beat Briacell Therap's score of -0.14 indicating that Portage Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Portage Biotech beats Briacell Therap on 9 of the 13 factors compared between the two stocks.

How does Portage Biotech compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Portage Biotech (NASDAQ:ATON) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Skye Bioscience presently has a consensus target price of $9.80, suggesting a potential upside of 1,080.72%. Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 4.5% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Skye Bioscience has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Portage Biotech's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Portage Biotech	N/A	N/A	N/A

Skye Bioscience is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A

In the previous week, Skye Bioscience had 7 more articles in the media than Portage Biotech. MarketBeat recorded 8 mentions for Skye Bioscience and 1 mentions for Portage Biotech. Skye Bioscience's average media sentiment score of 0.05 beat Portage Biotech's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Skye Bioscience beats Portage Biotech on 10 of the 14 factors compared between the two stocks.

How does Portage Biotech compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Portage Biotech (NASDAQ:ATON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 370.22%. Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Portage Biotech is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Portage Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Portage Biotech	N/A	N/A	N/A

Portage Biotech has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	170.95	-$16.59M	-$1.86	N/A
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A

In the previous week, Lisata Therapeutics had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for Lisata Therapeutics and 1 mentions for Portage Biotech. Lisata Therapeutics' average media sentiment score of 1.41 beat Portage Biotech's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Portage Biotech beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Portage Biotech compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Portage Biotech (NASDAQ:ATON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 1,035.07%. Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Tevogen Bio's higher probable upside, research analysts clearly believe Tevogen Bio is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.4% of Portage Biotech shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tevogen Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-610.37%
Portage Biotech	N/A	N/A	N/A

Tevogen Bio is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$9.50	N/A
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A

In the previous week, Tevogen Bio had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for Tevogen Bio and 1 mentions for Portage Biotech. Tevogen Bio's average media sentiment score of 0.74 beat Portage Biotech's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Portage Biotech beats Tevogen Bio on 8 of the 12 factors compared between the two stocks.

Get Portage Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATON vs. The Competition

Export

Metric	Portage Biotech	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$7.78M	$936.04M	$4.19B	$12.35B
Dividend Yield	N/A	4.84%	6.42%	5.35%
P/E Ratio	-0.04	1.49	22.70	25.39
Price / Sales	N/A	117.41	154.69	73.15
Price / Cash	N/A	20.07	53.46	56.33
Price / Book	-0.42	8.46	38.98	6.93
Net Income	-$6.77M	-$3.77M	$113.55M	$333.88M
7 Day Performance	N/A	11.22%	3.25%	0.03%
1 Month Performance	-2.06%	62.03%	5.03%	1.93%
1 Year Performance	N/A	114.66%	16.80%	33.14%

Portage Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATON Portage Biotech	1.3705 of 5 stars	$0.33 +3.8%	$2.00 +502.4%	N/A	$7.78M	N/A	N/A	6	Gap Up High Trading Volume
SNTI Senti Biosciences	3.1284 of 5 stars	$0.97 +1.8%	$8.50 +775.0%	-67.6%	$30.25M	$20K	N/A	4	News Coverage Positive News Earnings Report Analyst Forecast
BCTX Briacell Therap	0.2554 of 5 stars	$4.15 +2.0%	N/A	-86.5%	$30.09M	N/A	N/A	8	News Coverage Short Interest Increase
SKYE Skye Bioscience	2.3788 of 5 stars	$0.85 -3.0%	$9.80 +1,051.9%	-55.1%	$29.89M	N/A	N/A	11	News Coverage Earnings Report
LSTA Lisata Therapeutics	2.1228 of 5 stars	$3.26 -0.3%	$15.00 +360.1%	+41.3%	$29.70M	$170K	N/A	30	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATON) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Portage Biotech (ATON) Competitors

ATON vs. SNTI, BCTX, SKYE, LSTA, and TVGN

How does Portage Biotech compare to Senti Biosciences?

Summary

How does Portage Biotech compare to Briacell Therap?

Summary

How does Portage Biotech compare to Skye Bioscience?

Summary

How does Portage Biotech compare to Lisata Therapeutics?

Summary

How does Portage Biotech compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATON vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Portage Biotech (ATON) Competitors

ATON vs. SNTI, BCTX, SKYE, LSTA, and TVGN

How does Portage Biotech compare to Senti Biosciences?

Does the media refer more to ATON or SNTI?

Which has stronger earnings and valuation, ATON or SNTI?

Do analysts prefer ATON or SNTI?

Which has more risk & volatility, ATON or SNTI?

Is ATON or SNTI more profitable?

Do insiders and institutionals have more ownership in ATON or SNTI?

Summary

How does Portage Biotech compare to Briacell Therap?

Do institutionals and insiders have more ownership in BCTX or ATON?

Do analysts recommend BCTX or ATON?

Is BCTX or ATON more profitable?

Which has preferable earnings and valuation, BCTX or ATON?

Which has more volatility & risk, BCTX or ATON?

Does the media prefer BCTX or ATON?

Summary

How does Portage Biotech compare to Skye Bioscience?

Do analysts recommend SKYE or ATON?

Do institutionals and insiders have more ownership in SKYE or ATON?

Which has more volatility & risk, SKYE or ATON?

Is SKYE or ATON more profitable?

Which has preferable earnings and valuation, SKYE or ATON?

Does the media prefer SKYE or ATON?

Summary

How does Portage Biotech compare to Lisata Therapeutics?

Do analysts recommend LSTA or ATON?

Do insiders & institutionals have more ownership in LSTA or ATON?

Which has more volatility and risk, LSTA or ATON?

Is LSTA or ATON more profitable?

Which has higher valuation & earnings, LSTA or ATON?

Does the media favor LSTA or ATON?

Summary

How does Portage Biotech compare to Tevogen Bio?

Do analysts recommend TVGN or ATON?

Do insiders & institutionals have more ownership in TVGN or ATON?

Which has more volatility and risk, TVGN or ATON?

Is TVGN or ATON more profitable?

Which has higher valuation & earnings, TVGN or ATON?

Does the media favor TVGN or ATON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATON vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools